Limited data is available on the efficacy of direct acting anti-viral drugs on hepatitis C in drug users. The aim of this meta-analysis was to comprehensively analyze the efficacy and safety of LDV/SOF in drug users infected with the hepatitis C virus (HCV). The PubMed, Cochrane library, Embase and Web of Science databases were searched for articles published till April 2021 on HCV-positive drug users who were treated with ledipasvir/sofosbuvir (LDV/SOF). The primary endpoint was pooled sustained virological response at 12 weeks (SVR12) with 95% confidence interval (95% CI). Funnel plots and Egger’s test were used to assess the publication bias. A total of 12 studies and 711 subjects treated with LDV/SOF-based regimen for HCV were included, and the pooled SVR12 rate was 89.8% (95% CI 85.9–92.7). The pooled SVR12 rate of genotype 1 drug users was 92.4% (95% CI 88.6–95.0). Subgroup analysis showed that pooled SVR12 rates of patients treated with LDV/SOF and LDV/SOF ± RBV were 89.2% (95% CI 83.4–93.1), 90.4% (95% CI 83.6–94.5) respectively. In addition, the SVR12 rates were 88% (95% CI 70.7–95.7) for 8 weeks, 89.9% (95% CI 81.0–94.9) for 12 weeks and 82.2% (95% CI 24.9–98.5) for 24 weeks of treatment. LDV/SOF is a safe and relatively effective treatment for hepatitis C in drug users.

中文翻译：

---

雷迪帕韦/索磷布韦治疗吸毒者丙型肝炎的疗效和安全性：系统评价和荟萃分析


关于直接作用抗病毒药物对吸毒者丙型肝炎的疗效的数据有限。本荟萃分析的目的是全面分析 LDV/SOF 对感染丙型肝炎病毒 (HCV) 的吸毒者的疗效和安全性。检索了 PubMed、Cochrane 图书馆、Embase 和 Web of Science 数据库，查找截至 2021 年 4 月发表的关于接受雷迪帕韦/索磷布韦 (LDV/SOF) 治疗的 HCV 阳性吸毒者的文章。主要终点是 12 周时的持续病毒学应答 (SVR12)，置信区间为 95% (95% CI)。漏斗图和艾格检验用于评估发表偏倚。总共纳入了 12 项研究和 711 名接受基于 LDV/SOF 方案治疗 HCV 的受试者，汇总 SVR12 率为 89.8%（95% CI 85.9-92.7）。基因 1 型吸毒者的汇总 SVR12 率为 92.4%（95% CI 88.6–95.0）。亚组分析显示，接受 LDV/SOF 和 LDV/SOF ± RBV 治疗的患者的合并 SVR12 率分别为 89.2% (95% CI 83.4–93.1)、90.4% (95% CI 83.6–94.5)。此外，治疗 8 周时的 SVR12 率为 88% (95% CI 70.7–95.7)，治疗 12 周时的 SVR12 率为 89.9% (95% CI 81.0–94.9)，治疗 24 周时的 SVR12 率为 82.2% (95% CI 24.9–98.5) 。 LDV/SOF 是治疗吸毒者丙型肝炎的一种安全且相对有效的治疗方法。